CorMedix (CRMD) Expected to Announce Earnings on Wednesday

Key Points

• CorMedix is expected to release Q1 2026 results before the market opens on May 6, with analysts forecasting $0.46 EPS and $104.41M in revenue; a conference call is scheduled for May 5 at 8:30 AM ET.
• Positive Phase III ReSPECT topline results showed REZZAYO met the primary endpoint (non‑inferiority), materially de‑risking the program and supporting commercial potential in an estimated ~$2 billion prophylactic market.
• The board authorized a $75 million share buyback (up to ~12.3% of shares), while analysts remain mixed but the consensus rating is "Moderate Buy" with a $15 price target amid recent volatility.

CorMedix (NASDAQ:CRMD - Get Free Report) is expected to release its Q1 2026 results before the market opens on Wednesday, May 6th. Analysts expect CorMedix to post earnings of $0.46 per share and revenue of $104.4110 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 5, 2026 at 8:30 AM ET.

CorMedix (NASDAQ:CRMD - Get Free Report) last issued its earnings results on Thursday, March 5th. The company reported $0.16 earnings per share for the quarter, missing analysts' consensus estimates of $0.86 by ($0.70). The business had revenue of $128.62 million for the quarter, compared to analyst estimates of $127.02 million. CorMedix had a return on equity of 52.30% and a net margin of 52.31%.The firm's revenue for the quarter was up 312.1% on a year-over-year basis. During the same period last year, the company posted $0.22 earnings per share. On average, analysts expect CorMedix to post $1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

CorMedix Stock Down 3.2%

Shares of NASDAQ:CRMD opened at $7.57 on Wednesday. The stock has a market capitalization of $598.41 million, a price-to-earnings ratio of 3.79 and a beta of 1.41. CorMedix has a 1-year low of $6.13 and a 1-year high of $17.43. The company's fifty day moving average is $6.97 and its two-hundred day moving average is $8.89. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.94 and a current ratio of 2.11.

CorMedix announced that its Board of Directors has authorized a share buyback program on Monday, February 2nd that allows the company to buyback $75.00 million in outstanding shares. This buyback authorization allows the company to repurchase up to 12.3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company's board believes its shares are undervalued.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on CRMD. Zacks Research cut shares of CorMedix from a "hold" rating to a "strong sell" rating in a report on Tuesday, February 10th. D. Boral Capital restated a "buy" rating and set a $14.00 price target on shares of CorMedix in a research report on Monday. Truist Financial set a $16.00 price target on shares of CorMedix in a research report on Thursday, January 8th. Needham & Company LLC upped their price target on shares of CorMedix from $14.00 to $15.00 and gave the stock a "buy" rating in a research report on Monday. Finally, HC Wainwright lowered their price target on shares of CorMedix from $18.00 to $13.00 and set a "buy" rating for the company in a research report on Friday, January 23rd. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $15.00.

Key Stories Impacting CorMedix

Here are the key news stories impacting CorMedix this week:

• Positive Sentiment: Phase III ReSPECT topline: The primary endpoint was met — REZZAYO showed non-inferiority to standard prophylaxis for invasive fungal disease in allogeneic hematopoietic stem cell transplant patients, a result that materially de-risks the program and supports commercial potential in a roughly $2B prophylactic market. CorMedix Announces Positive Phase III ReSPECT Topline Results (GlobeNewswire)
• Positive Sentiment: Major media coverage emphasized the trial win and market opportunity, helping drive interest in the stock. CRMD stock jumps as antifungal drug clears key trial (MSN)
• Positive Sentiment: Citizens Jmp reaffirmed a "market outperform" rating and raised the price target to $19 — the highest PT among recent notes, implying ~150% upside from current levels and signaling strong sell‑side conviction post-trial. Citizens Jmp reaffirms market outperform, $19 PT (Benzinga)
• Positive Sentiment: Needham & Company raised its price target to $15 and maintained a "buy" rating, reinforcing analyst bullishness following the ReSPECT results. Needham raises PT to $15, buy (Benzinga)
• Positive Sentiment: Leerink Partners increased its price target to $14 and kept an "outperform" rating, another upward revision contributing to the consensus revision trend. Leerink raises PT to $14, outperform (Benzinga)
• Positive Sentiment: D. Boral Capital reaffirmed a "buy" rating with a $14 target, adding to the cluster of buy/outperform notes. D. Boral reaffirms buy, $14 PT (Benzinga)

Hedge Funds Weigh In On CorMedix

Institutional investors have recently modified their holdings of the company. Comerica Bank grew its position in shares of CorMedix by 454.6% during the third quarter. Comerica Bank now owns 2,690 shares of the company's stock worth $31,000 after acquiring an additional 2,205 shares during the last quarter. Canada Pension Plan Investment Board bought a new position in CorMedix in the 2nd quarter valued at about $42,000. Kestra Advisory Services LLC bought a new position in CorMedix in the 4th quarter valued at about $49,000. Caitong International Asset Management Co. Ltd grew its position in CorMedix by 666.6% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 4,385 shares of the company's stock valued at $51,000 after buying an additional 3,813 shares in the last quarter. Finally, Northwestern Mutual Wealth Management Co. bought a new position in CorMedix in the 3rd quarter valued at about $55,000. Institutional investors own 34.18% of the company's stock.

CorMedix Company Profile

CorMedix Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to reduce inflammation and prevent infection in critically and chronically ill patient populations. The company's lead product candidate, Neutrolin, is a catheter lock solution that combines taurolidine, heparin and citrate to prevent catheter-related bloodstream infections (CRBSIs) in patients undergoing hemodialysis. Neutrolin has received market authorization in the European Union under the CE Mark and is positioned to address a significant unmet medical need for infection prevention in dialysis centers.

In addition to its lead asset, CorMedix is advancing a biochemical portfolio aimed at mitigating complications associated with peritoneal dialysis and other high-risk procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.